Cipla shares dropped 5% after reporting a 57% year-on-year decline in net profit to Rs 676 crore, impacted by a fall in gRevlimid sales. Revenue remained flat at Rs 7,074 crore, with EBITDA also declining. The company plans upcoming launches to offset revenue decline and drive future growth.
